ArticleInternational journal of radiation oncology, biology, physics2026
The Impact of Lung and Heart Radiation Dose During Preoperative Chemoradiation on Overall Survival in Esophageal Cancer-A Post Hoc Analysis of CALGB 80803 (Alliance).
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of heart-sparing VMAT radiotherapy technique incorporating heart substructures for advanced NSCLC patients.Radiation oncology (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAlthough technical advances have allowed for reduced radiation doses to the lungs and heart when treating esophageal cancer, doses to these organs cannot yet be eliminated completely. We conducted a post hoc analysis of CALGB 80803 (Alliance) to evaluate whether the radiation doses delivered to the heart and lungs in a prospective study with robust quality assurance were associated with overall survival (OS), and we assessed the impact of intensity modulated radiation therapy (IMRT) on adherence with protocol-specified dose constraints. METHODS AND MATERIALS: Protocol-specified dose constraints were based on standard of care guidelines: total lung V10 Gy ≤ 40%, V20 Gy ≤ 20%, V30 Gy ≤ 15%, V40 Gy ≤ 10%; heart V30 Gy ≤ 30%. Post hoc dose cutpoints were calculated that best differentiated OS.
resultsA total of 225 patients underwent induction chemotherapy, where radiation modality data were available for 209/225 (92.8%); 127/209 (60.9%) were treated with IMRT. Adherence rates were high for each of the protocol-specified dose constraints: 162/209 (77.5%), 179/209 (85.6%), 207/209 (99.0%), 208/209 (99.5%), and 158/209 (75.6%); total lung: V10 Gy, V20 Gy, V30 Gy, V40 Gy, and heart V30 Gy, respectively. The heart V30 Gy ≤ 21% (P = .016) was associated with improved OS. Among patients with heart V30 Gy ≤ 21%, 8.5% and 32.3% received 3-dimensional conformal radiation therapy (3D-CRT) and IMRT, respectively (P < .001). Mean heart V30 Gy was lower in the IMRT versus the 3D-CRT group (24.7 vs 35.6; P < .001). On multivariable analysis, lung V10 Gy > 42% (hazard ratio [HR], 1.71; P = .017) and heart V30 Gy > 21% (HR, 1.86; P = .013) were associated with worse OS.
conclusionsMost patients on CALGB 80803 (Alliance) were treated with IMRT plans that met protocol-specified dose constraints for total lung and heart. Minimizing low dose volume to the lungs (V10 Gy) and minimizing heart V30 Gy were associated with a significant survival benefit. Total lung V10 Gy ≤ 42% and heart V30 Gy ≤ 21%, and utilization of IMRT over 3D-CRT, should be considered when designing radiation plans for patients with esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.